Aptose Biosciences Inc.
APS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.10M | 2.64M | 2.26M | 2.93M | 3.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.46M | 2.19M | 6.97M | 7.35M | 9.76M |
| Operating Income | -5.46M | -2.19M | -6.97M | -7.35M | -9.76M |
| Income Before Tax | -5.54M | -1.59M | -6.95M | -7.25M | -9.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.54M | -1.59M | -6.95M | -7.25M | -9.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.54M | -1.59M | -6.95M | -7.25M | -9.64M |
| EBIT | -5.46M | -2.19M | -6.97M | -7.35M | -9.76M |
| EBITDA | -5.46M | -2.18M | -6.96M | -7.34M | -9.74M |
| EPS Basic | -2.61 | -1.34 | -11.24 | -12.98 | -22.02 |
| Normalized Basic EPS | -1.63 | -0.84 | -7.02 | -8.12 | -13.76 |
| EPS Diluted | -2.61 | -1.34 | -11.24 | -12.98 | -22.02 |
| Normalized Diluted EPS | -1.63 | -0.84 | -7.02 | -8.12 | -13.76 |
| Average Basic Shares Outstanding | 2.13M | 1.19M | 618.70K | 558.50K | 437.80K |
| Average Diluted Shares Outstanding | 2.13M | 1.19M | 618.70K | 558.50K | 437.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |